Secondary end points
| Montelukast | Placebo | p Value | |
| Lung function at 4 weeks | |||
| FEV1 (litres) | 3.03 (0.74) | 3.20 (0.86) | 0.464 |
| FEV1 (% predicted) | 83.52 (26.6) | 89.27 (17.0) | 0.363 |
| RV (litres) | 1.92 (0.52) | 2.10 (0.75) | 0.884 |
| RV/TLC, % | 30.7 (7.2) | 32.0 (7.0) | 0.540 |
| Median (IQR) | |||
| No. of days as inpatient | 3 (2–4) | 3 (1–3.25) | 0.509 |
FEV1, forced expiratory volume in 1 s; RV, residual volume; TLC, total lung capacity.